TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Entrada Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.82+0.45 (+10.30%)
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Entrada Therapeutics has not reported a dividend
No dividend per share appears in Entrada Therapeutics's annual filings since fiscal 2019.